Pfizer – Optimizing Women’s Health Conditions in Canada – RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire within unit
Memorial Deadline: Wednesday 12th, July 2023
External Deadline: Wednesday 19th, July 2023
Description
| Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP. For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program. |
| Date RFP Issued: March 21, 2023
Geographic Scope: Canada Clinical Area: Women’s Health Link to full RFP: Optimizing Women’s Health Conditions in Canada Application Due Date: July 19, 2023 Specific Area of Interest: It is our intent to support Quality Improvement initiatives focused on menopause, uterine fibroids, endometriosis, and/or contraception in areas including improving the detection/diagnosis, optimizing treatment and/or management, and improving the dialogue between healthcare professionals and patients. |
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Jessica Romano, Grant Officer (jessica.romano@pfizer.com).